Novartis Seeks To Halt Stada's Generic Heart Failure Drug
Novartis has defended the validity of its U.K. patents for heart failure drug Entresto following a challenge from Stada, asking a London court to stop its rival launching a generic version...To view the full article, register now.
Already a subscriber? Click here to view full article